-
Solutions
-
News
Solutions
News
REGEN-αGEEK is a company initiated from the scientific and technological achievements of the First Prize of the National Science and Technology Progress Award. Based on nearly two decades of clinical translational research in stem cells and regenerative medicine, the company dedicated to creating the DASEA® bio-manufacturing platform, to achieve the “5” goals for the scalable manufacturing of biological products such as cells and exosomes: Digitalized, Automated, Scalable, Enclosed, Activated.
The DASEA® platform effectively addresses the limitations inherent in the traditional petri dish-based methods for large-scale cell cultivation. It achieves a notable reduction in the costs associated with cell production, concurrently enhancing the quality and stability of the cells. This platform offers an integrated solution tailored to meet the industrial-scale cell and derivative preparation needs of clients within the downstream cellular industry. The stem cells and exosomes prepared by DASEA® have obtained quality inspection reports from the NIFDC and been recognized by China NMPA, as well as several large tertiary hospitals to conduct multiple clinical trials (incl. COVID-19 and dry eye syndrome). These clinical studies have demonstrated excellent therapeutic outcomes. REGEN-αGEEK is dedicated to “Make regeneration clinically accessible and affordable”.
Learn about REGEN-αGEEK
Founder & Chief Scientist of REGEN-αGEEK
Awardee of the First Prize of National Science and Technology Progress Award of China (Top scientific award in China)
Expert of National Talent Program of China
Founding Director of Translational Research Center for Regenerative Medicine and 3D Printing, Guangzhou Medical University
Direction Leader, State Key Laboratory of Respiratory Diseases and Regenerative Medicine
Professor Zhiyong Zhang is a professor at Guangzhou Medical University (GMU) and the founding director of the translational research centre of regenerative medicine and 3D printing technologies at GMU, as well as the biomedical engineering research center of Guangdong Province.
Additionally, he serves as the group leader of the state key lab of respiratory disease in China. Previously, he was a professor/group leader at Shanghai Jiao Tong University and the national tissue engineering centre of China. He has been granted several talent scheme program awards, including the awardee of the First Prize of National Science and Technology Progress Award of China (Top scientific awards in China) and the National Talent Program of China (China's Recruitment Program of Global Experts), the “Eastern Scholar” Distinguished Professor, and the “Outstanding Medical Academic Leader”.
He has filed more than 30 patents, published over 80 academic papers in international journals such as advanced science, bioactive materials, small, biomaterials, and authored five book chapters, also he has awarded more than 20 research grants (30M RMB) and has been invited over 40 keynote lectures at international conferences.
Repair Regenerate Rejuvenate
Regeneration
Geek Power
· Vision ·
Make regeneration clinically accessible and affordable
· Mission ·
Striving towards an advanced mission to creating the finest regenerative medical innovations for societal advancement, familial health, and personal enhancement
· Values ·
Gratitude | Dedication | Innovation | Collaboration
01. Hardcore technology innovation and geek spirit
02. Long-termism
03. Skin in the game
2000
With the determination to study nothing but biomedical sciences, Professor Zhiyong Zhang is committed to becoming a regenerative medicine scientist/engineer.
With the determination to study nothing but biomedical sciences, Professor Zhiyong Zhang is committed to becoming a regenerative medicine scientist/engineer.
2005
Identify clinical needs from participating in the world's second case of "Osteogenesis Imperfecta (OI)" stem cell transplantation therapy.
Identify clinical needs from participating in the world's second case of "Osteogenesis Imperfecta (OI)" stem cell transplantation therapy.
2006
Development of the world's first dual-axis rotating bioreactor and 3D stem cell culture.
Development of the world's first dual-axis rotating bioreactor and 3D stem cell culture.
2009
R&D of biomimetic microcarriers and large-scale expansion of stem cells.
R&D of biomimetic microcarriers and large-scale expansion of stem cells.
2010
Proposing the “Four-Transformation Model for Clinical Translation in Regenerative Medicine", laying the theoretical foundation for the DASEA®.
Proposing the “Four-Transformation Model for Clinical Translation in Regenerative Medicine", laying the theoretical foundation for the DASEA®.
2011
Initiating the novel microcarrier development after Prof. Zhang honored the first research fund in China.
Initiating the novel microcarrier development after Prof. Zhang honored the first research fund in China.
2012
Selected as an expert of national talent program of China, becoming one of the youngest full professors and Ph.D.at Shanghai Jiao Tong University.
Selected as an expert of national talent program of China, becoming one of the youngest full professors and Ph.D.at Shanghai Jiao Tong University.
2014
Invited lectures at the highest-level academic forum (“Shuangqing Forum") of the national natural science foundation of China, where the “Lego Brick" transformation strategy was proposed.
Invited lectures at the highest-level academic forum (“Shuangqing Forum") of the national natural science foundation of China, where the “Lego Brick" transformation strategy was proposed.
2017
Established a research center and independently developed a serum-free medium system for stem cell culture, supporting clinical translation research of stem cells.
Established a research center and independently developed a serum-free medium system for stem cell culture, supporting clinical translation research of stem cells.
2021
Based on long-term research efforts in regenerative medicine translation, awarded the First Prize of national science and technology progress award of China, then established REGEN-αGEEK.
Based on long-term research efforts in regenerative medicine translation, awarded the First Prize of national science and technology progress award of China, then established REGEN-αGEEK.
2022
REGEN-αGEEK successfully completed series A and A+ rounds of financing, actively advancing industrialization research and development.
REGEN-αGEEK successfully completed series A and A+ rounds of financing, actively advancing industrialization research and development.
2023
Creating one-stop solution for large-scale preparation of stem cells/exosomes by the DASEA® bio-manufacturing platform.
Creating one-stop solution for large-scale preparation of stem cells/exosomes by the DASEA® bio-manufacturing platform.
2024
Recombinant collagen liquid dressing: Guangdong's first Class II medical device license; DASEA® biomimetic microcarriers: dual FDA filings.
Recombinant collagen liquid dressing: Guangdong's first Class II medical device license; DASEA® biomimetic microcarriers: dual FDA filings.
+86-0755-26412015
enquiry@regengeek.com
Headquarters: No. 301, Building 6, Juanhu Science and Innovation Park, No. 500, Shuiyue Pavilion East Road, Xiashi Street, Haining City, Jiaxing City, Zhejiang Province, China.
